MoonLake Immunotherapeutics MLTX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Oruka Therapeutics, Inc.ORKA

$1.81M+90.8%

Alumis Inc.ALMS

$35.66M+1,881%

Upstream Bio, Inc.UPB

$1.27M-30.8%

Kymera TherapeuticsKYMR

$76.14M-6.7%

ImmunityBio, Inc.IBRX

$40.77M+0.5%

Regeneron PharmaceuticalsREGN

$266.8M+13.8%

FAQ

What is MoonLake Immunotherapeutics's operating lease liabilities (total)?

MoonLake Immunotherapeutics (MLTX) reported operating lease liabilities (total) of $1.79M in Q1 2026.

How has MoonLake Immunotherapeutics's operating lease liabilities (total) changed year-over-year?

MoonLake Immunotherapeutics's operating lease liabilities (total) decreased by 30.7% year-over-year, from $2.57M to $1.79M.

What is the long-term trend for MoonLake Immunotherapeutics's operating lease liabilities (total)?

Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's operating lease liabilities (total) has grown at a 38.7% compound annual growth rate (CAGR), from $435.01K to $1.61M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.